Medication info
PME Rosuvastatin Tablets 10 mg (Rosuvastatin Calcium)

PME Rosuvastatin Tablets 10 mg (Rosuvastatin Calcium)

Prescription medicationTablet
Ingredient · strength
Rosuvastatin Calcium›10.419mg / 1 tablet
Manufacturer / importer
Pharmascience Korea
Appearance
Pink round film-coated tablets
Packaging
30 tablets/bottle
Approval status
Active

MFDS item code 201700504 · Approved 2017.01.26 · Insurance code 627600210

Summary

Main use
Improvement of dyslipidemia, inhibition of atherosclerosis progression, prevention of cardiovascular disease
Who uses it
Adults · Children
Adult dosage
1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with this drug, and should continue it throughout the treatment period. This drug may be taken at any time of day, with or without food. The initial dose is 5 milligrams once daily; the dose may be adjusted to a maintenance dose if greater LDL-cholesterol reduction is needed. The maintenance dose is 10 milligrams once daily, which is sufficient to achieve control in most patients. The maintenance dose should be adjusted appropriately at intervals of 4 weeks or longer according to LDL-cholesterol levels, treatment goals, and patient response; the dose may be increased to a maximum of 20 milligrams once daily. 3. Elderly patients: No dosage adjustment is necessary. 4. Patients with renal impairment: No dosage adjustment is necessary in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Particular caution is required when administering 20mg of this drug to patients with moderate renal impairment. 5. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score greater than 9. Do not administer this drug to patients with active liver disease. 6. Race: Because systemic exposure to this drug is increased in Asian patients, the recommended initial dose is 5 milligrams. Administration of the 40-milligram dose is contraindicated. 7. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 milligrams. Administration of the 40-milligram dose is contraindicated in some of these patients.
Children's dosage
Aged 10 years to 17 years: The usual dosage range is 5 milligrams to 20 milligrams once daily. (There are no clinical data on doses higher than 20 milligrams in pediatric patients.) The dose should be individually adjusted according to the recommended treatment goal for each patient. The dose should be adjusted at intervals of 4 weeks or longer. Children under 10 years: Safety and efficacy have not been established.

Ingredients

Importer
Pharmascience Korea

Efficacy & effects

Improvement of dyslipidemia, inhibition of atherosclerosis progression, prevention of cardiovascular disease

  • Hypercholesterolemia
  • heterozygous familial hypercholesterolemia
  • mixed dyslipidemia
  • homozygous familial hypercholesterolemia
  • atherosclerosis
  • heterozygous familial hypercholesterolemia
  • primary dysbetalipoproteinemia
  • elevated high-sensitivity C-reactive protein
  • hypertension
  • low HDL cholesterol levels
  • smoking
  • family history of early coronary artery disease
View approved original text

This medication is used when dietary control and exercise alone are insufficient for patients with primary hypercholesterolemia and mixed dyslipidemia. It is also used as an adjunct to diet or other lipid-lowering therapy in patients with familial hypercholesterolemia, specifically homozygous familial hypercholesterolemia. This medication effectively reduces total cholesterol and LDL cholesterol levels, delaying the progression of atherosclerosis. In pediatric patients aged 10 to 17 years with heterozygous familial hypercholesterolemia, it may be used as an adjunct to diet to reduce cholesterol levels if specific criteria are met. It also assists patients with primary dysbetalipoproteinemia as a dietary adjunct. Additionally, it contributes to reducing the risk of stroke, myocardial infarction, and revascularization procedures in high-risk patients with certain cardiovascular disease risk factors. This medication effectively improves cholesterol and cardiovascular disease risk.

Dosage and Administration

Adult dosage

1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with this drug, and should continue it throughout the treatment period. This drug may be taken at any time of day, with or without food. The initial dose is 5 milligrams once daily; the dose may be adjusted to a maintenance dose if greater LDL-cholesterol reduction is needed. The maintenance dose is 10 milligrams once daily, which is sufficient to achieve control in most patients. The maintenance dose should be adjusted appropriately at intervals of 4 weeks or longer according to LDL-cholesterol levels, treatment goals, and patient response; the dose may be increased to a maximum of 20 milligrams once daily. 3. Elderly patients: No dosage adjustment is necessary. 4. Patients with renal impairment: No dosage adjustment is necessary in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Particular caution is required when administering 20mg of this drug to patients with moderate renal impairment. 5. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score greater than 9. Do not administer this drug to patients with active liver disease. 6. Race: Because systemic exposure to this drug is increased in Asian patients, the recommended initial dose is 5 milligrams. Administration of the 40-milligram dose is contraindicated. 7. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 milligrams. Administration of the 40-milligram dose is contraindicated in some of these patients.

Children's dosage

Aged 10 years to 17 years: The usual dosage range is 5 milligrams to 20 milligrams once daily. (There are no clinical data on doses higher than 20 milligrams in pediatric patients.) The dose should be individually adjusted according to the recommended treatment goal for each patient. The dose should be adjusted at intervals of 4 weeks or longer. Children under 10 years: Safety and efficacy have not been established.

Precautions

This medication should not be administered to certain patients. For example, it should not be used in patients with a known allergy to any component of this medication, those with severely impaired liver function, or patients with muscle disorders. Additionally, pregnant or breastfeeding women, and women of childbearing age who do not use appropriate contraception should not take this medication. Patients who consume excessive alcohol or have a history of liver disease should use this medication with caution, and it is advisable to perform liver function tests before and during treatment. If symptoms of myalgia or muscle weakness occur, the patient should inform a physician immediately, and muscle enzyme levels should be assessed if necessary. This medication may interact with other drugs, so caution is needed, especially when taken with certain antivirals, immunosuppressants, antibiotics, etc. Taking this medication with certain drugs may increase its blood concentration, raising the risk of muscle damage, so consultation with a healthcare provider is essential. Pregnant or breastfeeding women should not use this medication, and women of childbearing age should ensure appropriate contraception during use. If pregnancy occurs, this medication should be discontinued immediately. In the event of overdose, there is no specific antidote; treatment should be symptomatic, and liver function and muscle enzyme tests are needed. This medication may cause dizziness, so caution is required when driving or operating machinery. It is important to consult healthcare professionals immediately if any unusual symptoms or suspected side effects occur while taking this medication.

Side effects

Hypersensitivity reactions including angioedema, diabetes, headache, dizziness, constipation, nausea, abdominal pain, pancreatitis, itching, rash, urticaria, myalgia, myopathy, rhabdomyolysis, weakness, polyneuropathy, amnesia, peripheral neuropathy, myasthenia gravis, cough, dyspnea, diarrhea, ocular myasthenia gravis, thrombocytopenia, jaundice, hepatitis, increased transaminases, Stevens-Johnson syndrome, drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome, lichenoid drug eruption, lupus-like syndrome, muscle rupture, arthralgia, immune-mediated necrotizing myopathy, hematuria, edema, depression, sleep disorders, interstitial lung disease, sexual dysfunction, gynecomastia, fatal and non-fatal liver failure, cognitive impairment, increased ALT, chest pain, muscle cramps, gout, erectile dysfunction, increased AST, numbness, sensory disturbances, chest discomfort, loss of appetite, abdominal bloating, abnormal liver function tests, syncope, generalized pain, fatigue

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly closed container to protect it from air and moisture, ideally at room temperature between 1 degree and 30 degrees Celsius. This storage method will help maintain the medication's effectiveness over time.

Appearance and packaging

Appearance

Pink round film-coated tablets

Package unit

30 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.